Expression of IL4 Induced Gene 1 in Patients With Cutaneous Melanoma: Value in Prognosis and/or in Predictive Response to Immune Checkpoint Inhibitors

Get Involved

Expression of IL4 Induced Gene 1 in Patients With Cutaneous Melanoma: Value in Prognosis and/or in Predictive Response to Immune Checkpoint Inhibitors

Study Purpose

To characterize and quantify immune cells expressing the Interleukine 4 induced gene 1 (IL4I1) immunosuppressive enzyme in the blood and in tissue of melanoma patients (primary tumor, sentinel lymph nodes and cutaneous metastases). Then, to compare the results obtained in different clinical settings:

- in cases of progression of the disease slower or faster compared to the prognosis established by clinical and pathological data.

- before and after treatments with immunotherapy (anti Programmed Death ligand 1 (anti-PD1) or anti-PD1 and anti Cytotoxic T Lymphocyte associated protein 4 (anti-CTLA-4)) and / or targeted therapies (BRAF inhibitors and /or methyl ethyl ketone (MEK)).

Recruitment Criteria

Accepts Healthy Volunteers Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms	No
Study Type An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes. An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes. Searching Both is inclusive of interventional and observational studies.	Interventional
Eligible Ages	18 Years and Over
Gender	All

More Inclusion & Exclusion Criteria

Inclusion Criteria:

- group 1: patients with primary thin melanoma (Breslow thickness less than or equal to1 mm) monitored for 10 years, having relapsed or not within 10 years after the diagnosis.

- patients with no other concomitant cancers requiring systemic treatment at the time of diagnosis of primary melanoma.

- patient or patient's family (in case of death) informed of the objectives and modalities of the study and not opposed to participation in the study.

- patient or patient's family (in case of death) not opposed to the use of part of the skin sample previously taken for the present research.

- group 2: patients with primary thick melanoma (Breslow greater than or equal to 3 mm) monitored for 5 years, having relapsed or not within 5 years after diagnosis.

- patient with no other concomitant cancers requiring systemic treatment at the time of diagnosis of primary melanoma.

- patient or patient's family (in case of death) informed of the objectives and modalities of the study and not opposed to participation in the study.

- patient or patient's family (in case of death) not opposed to the use of part of the skin sample previously taken for the present research.

- group 3: patient with melanoma (stages III or IV inoperable) and who are treated with immunotherapy and / or biotherapy.

- patient with no other concomitant cancers requiring systemic treatment at the time of diagnosis of primary melanoma and initiation of systemic treatment for melanoma.

- patient informed of the objectives and modalities of the study and having given informed and written consent to participate in the study.

Exclusion Criteria:

- groups 1 and 2: patient or family of the patient opposed (e) that part of the primary melanoma taken previously is used in the context of the present project.

- group 3 : - refusal of the patient to participate in the study.

- patient unable to understand the study and sign consent.

- patient with a known contraindication to xylocaine.

- patient not affiliated to a social security system (beneficiary or beneficiary's right) - adult subject to a legal protection measure

Trial Details

Trial ID: This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.	NCT04253080
Phase Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans. Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data. Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs. Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.	N/A
Lead Sponsor The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.	Assistance Publique - Hôpitaux de Paris
Principal Investigator The person who is responsible for the scientific and technical direction of the entire clinical study.	Armelle Blondel, MD, PhD
Principal Investigator Affiliation	Institut National de la Santé Et de la Recherche Médicale, France
Agency Class Category of organization(s) involved as sponsor (and collaborator) supporting the trial.	Other
Overall Status	Recruiting
Countries	France
Conditions The disease, disorder, syndrome, illness, or injury that is being studied.	Cutaneous Melanoma

Additional Details

The incidence of cutaneous melanoma is increasing, but the current prognostic parameters mainly based on histological data are insufficient to identify patients with high risk of recidive. In addition, current immunotherapies using PD-1 and/or CTLA-4 antibodies have long-lasting tumor control in a substantial fraction of patients but identify new markers of treatment resistance need further investigations. Clinical data highlight enzymes involved in amino acid catabolism as new potential prognostic markers in human melanoma. Among those, the IL4I1 phenylalanine oxidase may be a new relevant marker and may represent an easily targetable molecule for cancer immunotherapy. The current retrospective study is designed to evaluate whether a high proportion of IL4I1 positive cells within the primary tumor and/or sentinel lymph nodes allows to predict the risk of cancer recurrence from the clinical diagnosis. Immunofluorescence and immunohistochemistry will be performed. The longitudinal study of IL4I1 positive cells in the blood and cutaneous metastasis od patients will start before and after (three months and 1 year (or before in case of treatment resistance) the treatment with targeted therapy and/or immunotherapy as a first line. Treatment will be administered on an outpatient basis. No investigational or commercial cancer directed agents or therapies other than those described below may be administered. It is designed to evaluate whether patients that resist to treatments exhibit a high proportion of IL4I1 positive cells and how is regulated the enzyme in the course of the treatment.

Arms & Interventions

Arms

No Intervention: patients with primary thin melanoma < or = 1mm

patients with primary thin melanoma (Breslow thickness less than or equal 1 mm)

No Intervention: patients with primary thick melanoma > or = 3 mm

patients with primary thick melanoma (Breslow greater than or equal 3 mm)

Other: patient with melanoma who received treatment

patient with melanoma (stages III or IV inoperable) and who received first line treatment with immunotherapy and / or targeted therapies

Interventions

Biological: - Blood sample

Blood sample before treatment, 3 months after treatment and after 1 year or relapse or resumption of disease progression.

Biological: - Cutaneous melanoma biopsy

Cutaneous melanoma biopsy before treatment, 3 months after treatment and relapse or resumption of disease progression.

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.